Structure Therapeutics’ Stock Skyrockets Following Obesity Drug Breakthrough
Structure Therapeutics shares soared nearly 100% in Monday trading, following the announcement of exceptional results from its Phase 2b trial of aleniglipron, an oral obesity treatment. This treatment achieved up to 15.3% weight loss.
The ACCESS clinical program revealed that patients taking the highest 240mg dose of aleniglipron lost an average of 35.5 pounds over 36 weeks. This represents a 15.3% placebo-adjusted weight loss. Even the 120mg dose demonstrated significant results, with 11.3% weight loss. Notably, 70% of participants lost at least 10% of their body weight.
“These results position aleniglipron as a potentially game-changing oral alternative to current injectable obesity treatments like Wegovy and Zepbound,” said analysts following the announcement. The once-daily oral pill format could significantly improve patient access and adherence, compared to the weekly injections currently dominating the market.
Structure Therapeutics (NASDAQ: GPCR) closed at $68.84, marking a 99% gain as investors celebrated the breakthrough data. The company’s oral GLP-1 receptor agonist demonstrated a tolerability profile consistent with existing treatments, but with the added convenience of being in pill form.
The biotech firm plans to advance aleniglipron into Phase 3 development. This positions it to compete in the rapidly growing obesity treatment market, which is expected to reach hundreds of billions in annual sales.
Source: Investing.com